Kim Chihwa, Kwak Min Jung, Cho Sung Yoon, Ko Ah-Ra, Rheey Jinguen, Kwon Jeong-Yi, Chung Yokyung, Jin Dong-Kyu
Clinical Research Center, Samsung Biomedical Research Institute, Seoul, Republic of Korea.
Present Address: MOGAM Biotechnology Institute, Yongin, Republic of Korea.
Orphanet J Rare Dis. 2015 Sep 25;10:121. doi: 10.1186/s13023-015-0337-3.
Mucopolysaccharidosis type I (MPS I) is caused by the deficiency of alpha-L-iduronidase (IDUA), which is involved in the degradation of glycosaminoglycans (GAGs), such as heparan sulfate and dermatan sulfate in the lysosome. It has been reported that joint symptoms are almost universal in MPS I patients, and even in the case of attenuated disease, they are the first symptom that brings a child to medical attention. However, functional tests and biological markers have not been published for the evaluation of the limitations in joint and locomotion in animal model-mimicking MPS.
We generated IDUA knockout (KO) mice to observe whether they present impairment of joint function. KO mice were characterized phenotypically and tested dual-energy X-ray absorptiometry analysis (DEXA), open-field, rotarod, and grip strength.
The IDUA KO mice, generated by disruption between exon 6 and exon 9, exhibited clinical and laboratory findings, such as high urinary GAGs excretion, GAGs accumulation in various tissues, and significantly increased bone mineral density (BMD) in both female and male mice in the DEXA of the femur and whole bone. Remarkably, we observed a decrease in grasp function, decreased performance in the rotarod test, and hypo-activity in the open-field test, which mimic the limitations of joint mobility and decreased motor performance in the 6-min walk test in patients with MPS I.
We generated a new IDUA KO mouse, tested open field, rotarod and grip strength and demonstrated decrease in grip strength, decreased performance and hypo-activity, which may be useful for investigating therapeutic approaches, and studying the pathogenesis of joint and locomotion symptoms in MPS I.
I型黏多糖贮积症(MPS I)由α-L-艾杜糖醛酸酶(IDUA)缺乏所致,该酶参与溶酶体中糖胺聚糖(GAGs)如硫酸乙酰肝素和硫酸皮肤素的降解。据报道,关节症状在MPS I患者中几乎普遍存在,即使在病情较轻的情况下,也是导致儿童就医的首发症状。然而,尚未有用于评估模拟MPS的动物模型中关节和运动功能受限的功能测试及生物标志物发表。
我们构建了IDUA基因敲除(KO)小鼠,以观察其是否存在关节功能损害。对KO小鼠进行表型特征分析,并进行双能X线吸收测定分析(DEXA)、旷场试验、转棒试验和握力测试。
通过外显子6和外显子9之间的破坏构建的IDUA KO小鼠表现出临床和实验室检查结果,如尿GAGs排泄增加、各组织中GAGs蓄积,以及在股骨和全骨的DEXA中雌性和雄性小鼠的骨矿物质密度(BMD)显著增加。值得注意的是,我们观察到抓握功能下降、转棒试验表现降低以及旷场试验活动减少,这些模拟了MPS I患者6分钟步行试验中的关节活动受限和运动表现下降。
我们构建了一种新的IDUA KO小鼠,进行了旷场试验、转棒试验和握力测试,证明了握力下降、表现降低和活动减少,这可能有助于研究治疗方法以及MPS I中关节和运动症状的发病机制。